Login
Apyx Medical Corp logo

Apyx Medical Corp

apyxmedical.com

What Do They Do?

Sells body-contouring and tissue-treatment systems to cosmetic surgeons and hospitals, and develops electrosurgical equipment for medical-device makers.

How Do They Make Money?

Cosmetic-surgery customers buy Renuvion, AYON and J-Plasma; sales are generally counted when products ship or arrive under destination terms, with payment due under fixed terms. OEM makers buy generators, devices and accessories; most sales are counted at delivery, while qualifying made-to-order work is counted as it progresses.

revenue
SegmentShareRevenue
Surgical Aesthetics
Sold outright

86%
OEM
Sold outright

14%
FY2022: 17%

Who Are Their Customers?

In the U.S., physicians, cosmetic surgery offices and surgical centers buy Renuvion and AYON through Apyx's direct sales force; international sales mainly go through distributors. OEM customers include established medical-device makers and start-ups that need energy-based designs.

Customers above 10% of revenue, FY2024
of revenue from one customer

Do Revenues Turn Into Profits?

No. It lost $11.2M in FY2025.

Operating income, FY2025
−12% of revenue
▲ +66% (Loss) vs FY2024 (−$18.8M, −39%)
Net income, FY2025
−21% of revenue
▲ +52% (Loss) vs FY2024 (−$23.5M, −49%)
Free cash flow, FY2025
−17% of revenue
▲ +51% (Loss) vs FY2024 (−$18.8M, −39%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +9%
vs $12.9M in Q3 FY2025
Net income
▲ +10% (Loss)
vs −$2M in Q3 FY2025
Surgical Aesthetics share of revenue vs 85.9% in Q3 FY2025
  • Jun 17, 2026 Stavros Vizirgianakis appointed Executive Chairman He will provide strategic leadership and governance oversight and support management, investor engagement and corporate development.
  • May 11, 2026 FDA expands AYON clearance to include power liposuction

Growing. Revenue grew 9% in 4 years, from $48.5M in FY2021 to $52.8M in FY2025, about 2% a year.

AYON product line The earlier report describes Renuvion and J-Plasma; the latest adds AYON, an all-in-one body-contouring system that combines fat removal, contouring and tissue contraction.

China operations The earlier report said the China joint venture had not started principal operations; the latest says it has begun operations and that Renuvion launched in China.

Revenue over time
Surgical Aesthetics OEM Advanced Energy
$100M$50M$0

Who Do They Compete With?

Competes with Solta Medical and MicroAire Surgical Instruments

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support